The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node

James W Jakub, Marianne Huebner, Steve Shivers, Christopher Nobo, Christopher Puleo, William S. Harmsen, Douglas S. Reintgen

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: In melanoma, a direct relationship exists between the number of nodes involved with metastatic disease and prognosis. This study was undertaken to determine whether an individual with metastatic disease confined to the sentinel lymph nodes (SLNs) would have a better prognosis than individuals with metastatic disease that has spread to the non-SLNs, regardless of the number of nodes involved. Methods: The study group consists of 229 melanoma patients with a positive SLN who underwent regional nodal dissection. Cox proportional hazard regression models were used to assess association of the number of SLNs and non-SLNs involved with disease with overall survival (OS) and disease-free survival (DFS). Results: DFS and OS were unchanged regardless of how many SLNs were positive, as long as all disease was confined to SLNs. Among 183 patients without involvement of non-SLNs, OS remained the same despite an increasing number of SLNs involved (P = .59). This was true after controlling for ulceration, Breslow depth, age, sex, and adjuvant treatment. Once disease was present beyond the SLN, DFS and OS were negatively affected. Among patients with involvement of non-SLNs, there was no statistically significant association between the number of positive SLNs and survival. The risk of mortality increased with the number of non-SLNs involved with metastatic disease (P < .001). Conclusions: The number of regional nodes involved with metastatic disease does not affect DFS and OS if disease is confined to the SLNs. Consideration should be given to specifying SLN versus non-SLN involvement in the American Joint Committee on Cancer staging manual.

Original languageEnglish (US)
Pages (from-to)2245-2251
Number of pages7
JournalAnnals of Surgical Oncology
Volume16
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Melanoma
Lymph Nodes
Disease-Free Survival
Survival
Sentinel Lymph Node
Neoplasm Staging
Proportional Hazards Models
Dissection
Mortality

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node. / Jakub, James W; Huebner, Marianne; Shivers, Steve; Nobo, Christopher; Puleo, Christopher; Harmsen, William S.; Reintgen, Douglas S.

In: Annals of Surgical Oncology, Vol. 16, No. 8, 08.2009, p. 2245-2251.

Research output: Contribution to journalArticle

Jakub, James W ; Huebner, Marianne ; Shivers, Steve ; Nobo, Christopher ; Puleo, Christopher ; Harmsen, William S. ; Reintgen, Douglas S. / The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node. In: Annals of Surgical Oncology. 2009 ; Vol. 16, No. 8. pp. 2245-2251.
@article{e359644eb82942469108164c37fe6dbf,
title = "The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node",
abstract = "Background: In melanoma, a direct relationship exists between the number of nodes involved with metastatic disease and prognosis. This study was undertaken to determine whether an individual with metastatic disease confined to the sentinel lymph nodes (SLNs) would have a better prognosis than individuals with metastatic disease that has spread to the non-SLNs, regardless of the number of nodes involved. Methods: The study group consists of 229 melanoma patients with a positive SLN who underwent regional nodal dissection. Cox proportional hazard regression models were used to assess association of the number of SLNs and non-SLNs involved with disease with overall survival (OS) and disease-free survival (DFS). Results: DFS and OS were unchanged regardless of how many SLNs were positive, as long as all disease was confined to SLNs. Among 183 patients without involvement of non-SLNs, OS remained the same despite an increasing number of SLNs involved (P = .59). This was true after controlling for ulceration, Breslow depth, age, sex, and adjuvant treatment. Once disease was present beyond the SLN, DFS and OS were negatively affected. Among patients with involvement of non-SLNs, there was no statistically significant association between the number of positive SLNs and survival. The risk of mortality increased with the number of non-SLNs involved with metastatic disease (P < .001). Conclusions: The number of regional nodes involved with metastatic disease does not affect DFS and OS if disease is confined to the SLNs. Consideration should be given to specifying SLN versus non-SLN involvement in the American Joint Committee on Cancer staging manual.",
author = "Jakub, {James W} and Marianne Huebner and Steve Shivers and Christopher Nobo and Christopher Puleo and Harmsen, {William S.} and Reintgen, {Douglas S.}",
year = "2009",
month = "8",
doi = "10.1245/s10434-009-0530-5",
language = "English (US)",
volume = "16",
pages = "2245--2251",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node

AU - Jakub, James W

AU - Huebner, Marianne

AU - Shivers, Steve

AU - Nobo, Christopher

AU - Puleo, Christopher

AU - Harmsen, William S.

AU - Reintgen, Douglas S.

PY - 2009/8

Y1 - 2009/8

N2 - Background: In melanoma, a direct relationship exists between the number of nodes involved with metastatic disease and prognosis. This study was undertaken to determine whether an individual with metastatic disease confined to the sentinel lymph nodes (SLNs) would have a better prognosis than individuals with metastatic disease that has spread to the non-SLNs, regardless of the number of nodes involved. Methods: The study group consists of 229 melanoma patients with a positive SLN who underwent regional nodal dissection. Cox proportional hazard regression models were used to assess association of the number of SLNs and non-SLNs involved with disease with overall survival (OS) and disease-free survival (DFS). Results: DFS and OS were unchanged regardless of how many SLNs were positive, as long as all disease was confined to SLNs. Among 183 patients without involvement of non-SLNs, OS remained the same despite an increasing number of SLNs involved (P = .59). This was true after controlling for ulceration, Breslow depth, age, sex, and adjuvant treatment. Once disease was present beyond the SLN, DFS and OS were negatively affected. Among patients with involvement of non-SLNs, there was no statistically significant association between the number of positive SLNs and survival. The risk of mortality increased with the number of non-SLNs involved with metastatic disease (P < .001). Conclusions: The number of regional nodes involved with metastatic disease does not affect DFS and OS if disease is confined to the SLNs. Consideration should be given to specifying SLN versus non-SLN involvement in the American Joint Committee on Cancer staging manual.

AB - Background: In melanoma, a direct relationship exists between the number of nodes involved with metastatic disease and prognosis. This study was undertaken to determine whether an individual with metastatic disease confined to the sentinel lymph nodes (SLNs) would have a better prognosis than individuals with metastatic disease that has spread to the non-SLNs, regardless of the number of nodes involved. Methods: The study group consists of 229 melanoma patients with a positive SLN who underwent regional nodal dissection. Cox proportional hazard regression models were used to assess association of the number of SLNs and non-SLNs involved with disease with overall survival (OS) and disease-free survival (DFS). Results: DFS and OS were unchanged regardless of how many SLNs were positive, as long as all disease was confined to SLNs. Among 183 patients without involvement of non-SLNs, OS remained the same despite an increasing number of SLNs involved (P = .59). This was true after controlling for ulceration, Breslow depth, age, sex, and adjuvant treatment. Once disease was present beyond the SLN, DFS and OS were negatively affected. Among patients with involvement of non-SLNs, there was no statistically significant association between the number of positive SLNs and survival. The risk of mortality increased with the number of non-SLNs involved with metastatic disease (P < .001). Conclusions: The number of regional nodes involved with metastatic disease does not affect DFS and OS if disease is confined to the SLNs. Consideration should be given to specifying SLN versus non-SLN involvement in the American Joint Committee on Cancer staging manual.

UR - http://www.scopus.com/inward/record.url?scp=67650970109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650970109&partnerID=8YFLogxK

U2 - 10.1245/s10434-009-0530-5

DO - 10.1245/s10434-009-0530-5

M3 - Article

C2 - 19517194

AN - SCOPUS:67650970109

VL - 16

SP - 2245

EP - 2251

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 8

ER -